Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors.

Bilici, AhmetGumus, MahmutOdabas, HaticeKandemir, NurtenDemirci, UmutCihan, SenerBayoglu, Ibrahim VedatUstaalioglu, Bala Basak OvenOzturk, TurkanTurkmen, EsmaUrakci, ZuhatSeker, Mehmet MetinGunaydin, YusufSelcukbiricik, FatihTuran, NedimSevinc, Alper2019-07-272019-07-282019-07-272019-07-2820160732-183X1527-7755https://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e16051https://hdl.handle.net/20.500.12418/7330Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2016 -- Chicago, IL…en10.1200/JCO.2016.34.15_suppl.e16051info:eu-repo/semantics/closedAccessOutcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors.Conference Object3415WOS:000404711500029Q1